Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday

Heron Therapeutics (NASDAQ:HRTX) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share and revenue of $37.37 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Heron Therapeutics Stock Down 5.1 %

HRTX opened at $1.68 on Wednesday. Heron Therapeutics has a twelve month low of $1.04 and a twelve month high of $3.93. The company has a 50-day moving average price of $1.66 and a 200 day moving average price of $1.71. The company has a market cap of $255.52 million, a PE ratio of -9.33 and a beta of 1.60.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HRTX. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, December 4th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.